This month, we are highlighting our Healthier Communities initiative to bring awareness to the work we are leading in collaboration with our customers, communities, and colleagues to help advance #healthequity globally. Listen to the latest episode of #ScienceWithATwist as our program executives Fred Lowery and Meron Mathias discuss how we leverage science, innovation, and customer relationships to build thriving health ecosystems around the world. https://lnkd.in/guQQX775
Thermo Fisher Scientific
Biotechnology Research
Waltham, MA 1,589,910 followers
The World Leader In Serving Science
About us
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
- Website
-
https://www.thermofisher.com
External link for Thermo Fisher Scientific
- Industry
- Biotechnology Research
- Company size
- 10,001 employees
- Headquarters
- Waltham, MA
- Type
- Public Company
- Specialties
- Analytical Instruments, Laboratory Supply Chain Programs and eCommerce, Laboratory Equipment, Lab Services, Specialty Diagnostics, Life Sciences, Pharma Services, and CDMO
Locations
-
Primary
168 Third Avenue
Waltham, MA, US
Employees at Thermo Fisher Scientific
-
Jane Li
Senior Director, Pharma CDx and CRO Partnership
-
Veronika Galvez,
Category Manager at Thermo Fisher Scientific
-
Steve Marteney
Senior Technology and Software Development Leader
-
Toshiko Banno Hadden
IT Director (RETIRED), Enterprise Technology & Operations Thermo Fisher Scientific
Updates
-
For years, clinical trials have not accurately reflected the diversity within our population, leading to inequities in healthcare and scientific research. Yesterday, we hosted a Congressional briefing with industry leaders and patient advocates dedicated to bridging the gap for a more equitable future in science. Thank you to our panelists: Thermo Fisher Scientific’s Dr. Rose Blackburne, MD, MBA, Vice President, Medical Science and Strategy, and Global Head of General Medicine and Women’s Health, Vanderbilt University Medical Center’s Dr. Sheila Kusnoor, National Minority Quality Forum’s Dr. Salvatore (Salvo) Alesci and Cystic Fibrosis Foundation’s Ashleigh Tharp. Cross-industry collaboration is essential to support scientific discovery and understand how we can better connect communities to ongoing research and treatment discovery.
-
-
We had the thrill of witnessing more than 3,000 transplant recipients from around the world, joined by living donors, donor families, and caregivers, as they competed earlier this month in the 2024 Transplant Games of America. Our transplant diagnostic solutions help match patients with appropriate donors. It was inspiring to see members of the transplant community celebrate the gift of life by participating in more than 20 events. We are proud to support this amazing community.
-
-
Once again, Thermo Fisher has been named to the Fortune 500 annual list of the largest companies in the U.S. Thank you to our more than 120,000 colleagues for making this possible. Their passion for our Mission to enable our customers to make the world healthier, cleaner and safer fuels our growth and success, and we look forward to what we will accomplish together as we continue to enable scientific breakthroughs and build a brighter future for all.
-
While there are about 30 FDA-approved cell and gene therapies on the market, access still remains a key barrier to helping patients who can potentially benefit. Our Jon Chesnut, senior director, cell biology, shares his perspective on how our industry can help overcome these barriers with The Medicine Maker. Read more:
-
Our president of analytical services, Leon Wyszkowski, recently shared how a recent capabilities expansion at our Middleton, Wisconsin, site will help accelerate development of life-saving therapies and support our customers who provide them to patients in need. The state’s Governor Tony Evers also attended the ribbon-cutting ceremony to commemorate the event and to highlight the positive economic impact the local community will see because of the site’s expansion. Watch the news coverage from WKOW-ABC 27 http://spr.ly/6044iZ5CQ
Ribbon cut on Thermo Fisher expansion, 350 jobs coming to Middleton
wkow.com
-
We’re excited to announce the expansion of our Basel, Switzerland, site where the introduction of innovative robotics and integrated solutions for clinical trials support will help the European pharmaceutical and #biotech industry meet critical needs in the drug development process and accelerate delivery of new therapies to the patients who need them most.
-
-
We’re excited to collaborate with the National Cancer Institute (NCI) on the myeloMATCH umbrella trial in an effort to help advance research in precision oncology. This groundbreaking program will fast-track acute myeloid leukemia patient enrollment in clinical trials informed by genomic insights provided by our next-day, sequencing technology. Accelerating this research provides hope for a future in which patients will have access to the right therapies based on their genomic profile and transform their cancer treatment journey. https://bit.ly/4f1iACO
-
We’re excited to share that we’ve completed the acquisition of Olink Proteomics. Olink provides targeted protein biomarker discovery and precision proteomics. Together we will further strengthen our commitment to accelerate discoveries and scientific breakthroughs through advanced proteomics solutions. This is an exciting step for Thermo Fisher as we continue to expand our next-generation life sciences and mass spectrometry offerings for research and precision medicine. We look forward to welcoming Olink colleagues into the organization! Learn more: https://bit.ly/4cToTX8
Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period
newsroom.thermofisher.com
Affiliated pages
Similar pages
Browse jobs
Stock
TMO
NYSE
20 minutes delay
$574.79
22.55 (4.083%)
- Open
- 552.92
- Low
- 552.65
- High
- 575.25
Data from Refinitiv
See more info on